Correspondence: Cold Perfusion vs. Static Cold Storage of Deceased-Donor Kidneys — at 10 Years https://t.co/IsPje4CVR1 #Surgery #Nephrology

The medium-term oncological safety of MRI-led prostate cancer diagnostic pathway is unclear. We followed up 1266 patients and summarised our findings into 3 key messages. @IP_London @EUplatinum Read full paper for free: https://t.co/d7Ma9cUBXr

🚨 Revisiting Active Surveillance in #ProstateCancer 👉New @TheLancetOncol commentary challenges how far we can stretch “low-risk” 🚦 @DrSpratticus @EdwardSchaeffer 🔹 Active surveillance is safe for Grade Group 1, but… 🔹 For Grade Group 2, long-term data are thin 📉 🔹

Urolgoists @Adam_Weiner535 & @mleapman discuss evolving approaches to active surveillance in #prostatecancer, particularly among patients with intermediate-risk disease. [Watch]->

Optimised use of radioligand therapy in mCRPC #ESMO25

Germline and somatic genetic testing in advanced prostate cancer: Practical considerations and challenges #ESMO25

1/2 KN905 Enfortumab Vedotin + Pembro continues to transform bladder cancer in spectacle fashion. In cisplatin ineligible operable disease it beats cystectomy with EFS HR 0.4, OS HR 0.5. pCR of 57% is much ⬆️ than anything before #ESMO25 pCR> 50% questions unselected surgery

STOPCAP at #ESMO26 Benefit of #radiotherapy in de novo M1 #prostatecancer on OS & PFS. Restricted to <5 bone or low volume mets on conventional imaging. No interaction with other patient/tumor characteristics.

1/2 Just published in @JAMAOnc: 15-year outcomes of Active Monitoring, Surgery, and Radiotherapy for cribriform-positive and cribriform-negative prostate cancer in the ProtecT trial. Secondary analysis based on centralised biopsy review🔬 Article:

LBA91 – AMPLITUDE Trial (PROs) #ESMO25 🧬 HRRm mHSPC: Niraparib + abiraterone + prednisone maintained baseline QoL while improving rPFS vs AA+P. ✅ No clinically meaningful HRQoL differences (FACT-P, EQ-5D-5L, BPI-SF). 📈 ≥94% PRO compliance; pts largely “not bothered” by side

2420MO – STOPCAP Meta-analysis #ESMO25 📊 Pooled IPD from PEACE-1 & STAMPEDE: prostate RT in synchronous mHSPC. ⚖️ No overall OS benefit (HR 0.93, p=0.11) ✅ Low-volume benefit: HR 0.79 → +7.7% 5-yr OS ✅ ≤4 bone mets: HR 0.84 (+4.9%) ➡️ Benefit confined to low-volume,

At @myESMO #esmo2025 Berlin, I had the privilege to present the #ALBAN trial (GETUG–AFU 37), an academic phase III study led by @AFUrologie & @GETUG_Unicancer @LaCarine1 together with my outstanding co-PI @y_loriot ,co-investigators @PignotG @champiatMD @PrRomainMATHIEU

🧬 Cribriform architecture changes the story in localized prostate cancer. 🔥 ProtecT 15-year biopsy re-review shows who really needs treatment vs surveillance. 🎯 n = 712 with available slides (13 % cribriform+) 💊 Arms: ▫️ Active monitoring ▫️ Radical prostatectomy ▫️

👓Our RIDERS #trial shows how #AugmentedReality guidance allows to reduce positive surgical margins during #robotic prostatectomy @EUplatinum @danieleamparore @PorpigliaF 👉 https://t.co/o8K68BFwDL

🧠 New in European Urology Erectile Dysfunction: Update on Clinical Management by @paolo_capog et al. @maartenalbersen @castiglionfabio Eur Urol. 2025;88:388–399 👉 https://t.co/DI6XHcFpFS This comprehensive review summarizes current and emerging strategies in the management of

🥁#ESMO25 ABSTRACT RELEASE DAY🥁 #ESMO25 is shaping up to be one of most impactful conferences in recent memory with #PracticeChangingData in Prostate, Bladder and Kidney Cancers! 💫See list of highlighted abstracts 👇

🚨Just in @NatureMedicine 👉 results from the Ph 3 AMPLITUDE trial: adding niraparib to abiraterone ⬆️outcomes in HRR-altered mHSPC #prostatecancer 👉 RPFS ⬆️: BRCA 1/2 HR 0.52, P < 0.0001; ITT HR 0.63, P =0.0001 Open link👉 https://t.co/BYx1L9i7GC @PCFnews @OncoAlert @urotoday

💡 Word of Wisdom - ARANOTE trial The ARANOTE trial reinforces the role of darolutamide + ADT as a well-tolerated, chemotherapy-free intensification strategy for metastatic hormone-sensitive prostate cancer. 🔹 Significant improvement in rPFS (HR 0.54, p < 0.0001) 🔹 Lower

AMPLITUDE trial of niraparib abi just published - 1st confirmation of efficacy with PARPi in HRR-mutant mHSPC, with notable benefit in the BRCA subgroup.

Would surgery add survival benefit to the systemic treatment in patients with oligometastatic prostate cancer ? A new data highlights this; 👉Adding radical prostatectomy to best systemic therapy cut 5-yr cancer-specific mortality from 23% to 13% (HR 0.39, p=0.045). Early